Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

References

• Organization WH. Schizophrenia. 2015 [updated 2015; cited 2015 Sept 2]. Available from: http://www.who.int/mental_health/management/schizophrenia/en/
   Google Scholar
• Lauber C, Keller C, Eichenberger A, et al. Family burden during exacerbation of schizophrenia: quantification and determinants of additional costs. Int J Social Psychiatry. 2005;51(3):259–264.
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–1131.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2197–2223.
   Web of Science ®Google Scholar
• Neil AL, Carr VJ, Mihalopoulos C, et al. Costs of psychosis in 2010: findings from the second Australian National Survey of Psychosis. Aust N Z J Psychiatry. 2014;48(2):169–182.
   PubMed Web of Science ®Google Scholar
• Melau M, Jeppesen P, Thorup A, et al. The effect of five years versus two years of specialised assertive intervention for first episode psychosis-OPUS II: study protocol for a randomized controlled trial. Trials. 2011;12(1):72.
   PubMedGoogle Scholar
• Hastrup LH, Kronborg C, Bertelsen M, et al. Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study). Br J Psychiatry. 2013;202(1):35–41.
   PubMed Web of Science ®Google Scholar
• Stant AD, TenVergert EM, Wunderink L, et al. Economic consequences of alternative medication strategies in first episode non-affective psychosis. Eur Psychiatry. 2007;22(6):347–353.
   PubMed Web of Science ®Google Scholar
• Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10(1):23.
   PubMed Web of Science ®Google Scholar
• Angelo C, Vittorio M, Anna M, et al. Cost-effectiveness of treating first-episode psychosis: five-year follow-up results from an Italian early intervention programme. Early Interv Psychiatry. 2011;5(3):203–211.
   PubMed Web of Science ®Google Scholar
• Carr VJ, Neil AL, Halpin SA, et al. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Australas Psychiatry. 2003;37(1):31–40.
   Google Scholar
• Ising HK, Smit F, Veling W, et al. Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. Psychol Med. 2014;2014:1–12.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Philadelphia, USA: American Psychiatric Pub; 2013.
   Google Scholar
• Edwards J, McGorry PD. Implementing early intervention in psychosis: A guide to establishing psychosis services. London: Taylor & Francis; 2002.
   Google Scholar
• Larsen TK, Friis S, Haahr U, et al. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand. 2001;103(5):323–334.
   PubMed Web of Science ®Google Scholar
• Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The Critical Period Hypothesis. Br J Psychiatry Suppl. 1998;1998(172):53–59.
   Google Scholar
• Jeppesen P, Petersen L, Thorup A, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008;38(08):1157–1166.
   PubMedGoogle Scholar
• Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975–983.
   PubMed Web of Science ®Google Scholar
• McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust. 2007;187(7 Suppl):S8–10.
   PubMed Web of Science ®Google Scholar
• McCrone P, Singh SP, Knapp M, et al. The economic impact of early intervention in psychosis services for children and adolescents. Early Interv Psychiatry. 2013;7(4):368–373.
   PubMed Web of Science ®Google Scholar
• Cullberg J, Mattsson M, Levander S, et al. Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish “Parachute Project” and Two Comparison Groups. Acta Psychiatr Scand. 2006;114(4):274–281.
   PubMed Web of Science ®Google Scholar
• Breitborde NJ, Woods SW, Srihari VH. Multifamily psychoeducation for first-episode psychosis: A cost-effectiveness analysis. Psychiatric Serv. 2009;60(11):1477–1483.
   PubMed Web of Science ®Google Scholar
• McCrone P, Craig TK, Power P, et al. Cost-effectiveness of an early intervention service for people with psychosis. Br J Psychiatry. 2010;196(5):377–382.
   PubMed Web of Science ®Google Scholar
• Mihalopoulos C, McGorry PD, Carter RC. Is phase-specific, community-oriented treatment of early psychosis - an economically viable method of improving outcome? Acta Psychiatr Scand. 1999;100(1):47–55.
   PubMed Web of Science ®Google Scholar
• Mihalopoulos C, Harris M, Henry L, et al. Is early intervention in psychosis cost-effective over the long term? Schizophr Bull. 2009;35(5):909–918.
   PubMed Web of Science ®Google Scholar
• Correll CU, Galling B, Pawar A, et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555–565. PubMed PMID: 29800949; PubMed Central PMCID: PMCPMC6137532. eng.
   PubMed Web of Science ®Google Scholar
• Kruse G, Wong BJ, Duh MS, et al. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. PharmacoEconomics. 2015;33(10):1049–1067.
   PubMed Web of Science ®Google Scholar
• Bobes J, Cañas F, Rejas J, et al. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuro Psychopharmacol Biol Psychiatry. 2004;28(8):1287–1297.
   PubMed Web of Science ®Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. PharmacoEconomics. 2016;34(4):363–391.
   PubMed Web of Science ®Google Scholar
• Drukker M, Joore M, van Os J, et al. The use of a Cumulative Needs for Care Monitor for individual treatment v. care as usual for patients diagnosed with severe mental illness, a cost-effectiveness analysis from the health care perspective. Epidemiol Psychiatr Sci. 2012;21(04):381–392.
   PubMedGoogle Scholar
• Lin I, Muser E, Munsell M, et al. Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis. J Med Econ. 2015;18(3):219–229.
   PubMed Web of Science ®Google Scholar
• McCrone P, Knapp M, Dhanasiri S. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–1131.
   Web of Science ®Google Scholar
• O’Day K, Rajagopalan K, Meyer K, et al. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res. 2013;5:459–470.
   PubMedGoogle Scholar
• Phanthunane P, Vos T, Whiteford H, et al. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. Cost Eff Resour Allocation. 2011;9(1):6.
   PubMedGoogle Scholar
• Tempest M, Sapin C, Beillat M, et al. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. J Ment Health Policy Econ. 2015;18(4):185–200.
   PubMed Web of Science ®Google Scholar
• Valmaggia L, McCrone P, Knapp M, et al. Economic impact of early intervention in people at high risk of psychosis. Psychol Med. 2009;39(10):1617–1626.
   PubMed Web of Science ®Google Scholar
• Zeidler J, Mahlich J, Greiner W, et al. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy. 2013;11(5):509–521.
   PubMedGoogle Scholar
• McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry. 2006;40(8):616–622.
   PubMed Web of Science ®Google Scholar
• Vos, Theo, University of Queensland. School of Population Health. Centre for Burden of Disease and Cost Effectiveness and Deakin University. Deakin Population Health Strategic Research Centre Assessing cost-effectiveness in prevention: (ACE-Prevention): final report. Centre for Burden of Disease and Cost Effectiveness, School of Population Health, University of Queensland, Brisbane, 2010.
   Google Scholar
• McGorry PD, Mei C. Ultra-high-risk paradigm: lessons learnt and new directions. Evid Based Ment Health. 2018;21(4):131–133.
   PubMed Web of Science ®Google Scholar
• van der Gaag M, Smit F, Bechdolf A, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res. 2013;149(1–3):56–62.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Yung A, McGorry P, et al. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med. 2014;44(1):17–24.
   PubMed Web of Science ®Google Scholar
• Zorginstituut Nederland. Zorgstandaard Psychose 2017. [cited 2019 Jan 14].  Available from: https://www.zorginzicht.nl/bibliotheek/schizofrenie-inclusief-module-vroege-psychose/Paginas/Home.aspx
   Google Scholar
• Nelson B, Yuen HP, Wood SJ, et al. Long-term Follow-up of a Group at Ultra High Risk (“Prodromal”) for Psychosis: the PACE 400 StudyFollow-up of Prodromal PsychosisFollow-up of Prodromal Psychosis. JAMA Psychiatry. 2013;70(8):793–802.
   PubMed Web of Science ®Google Scholar
• Ising HK, Lokkerbol J, Rietdijk J, et al. Four-Year Cost-effectiveness of Cognitive Behavior Therapy for Preventing First-episode Psychosis: the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. Schizophr Bull. 2017;43.2:365-374.
   PubMed Web of Science ®Google Scholar
• Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Diemen: Zorginstituut Nederland; 2015.
   Google Scholar
• Naimark DM, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making. 2008 Sep-Oct;28(5):706–712. . PubMed PMID: 18448700; eng.
   PubMed Web of Science ®Google Scholar
• Veling W, van der Wal M, Jansen S, et al. Handboek Vroege Psychose. Amsterdam: Uitgeverij SWP; 2012.
   Google Scholar
• Vemer P, Ramos IC, Van Voorn G, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349–361.
   PubMed Web of Science ®Google Scholar
• Statistics Netherlands. Sterfte; geslacht, leeftijd (op 31 december) en burgerlijke staat 1950-2014. 2014 [2018 Nov 12]. Available from http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=37530ned&D1=1&D2=101-120&D3=0&D4=l&HDR=T,G1&STB=G2,G3&VW=T
   Google Scholar
• Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012 Mar;69(3):220–229. . PubMed PMID: 22393215; eng.
   PubMed Web of Science ®Google Scholar
• Austin SF, Mors O, Secher RG, et al. Predictors of recovery in first episode psychosis: the OPUS cohort at 10 year follow-up. Schizophr Res. 2013 Oct;150(1):163–168.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Cappucciati M, Bonoldi I, et al. Prognosis of brief psychotic episodes: a meta-analysis. JAMA Psychiatry. 2016;73(3):211–220.
   PubMed Web of Science ®Google Scholar
• Lokkerbol J, Lokman S, Janssen R, et al. Rendeert zorgonderzoek in de GGZ? Ned Tijdschr Evidence Based Pract. 2017;15(2):8–10.
   Google Scholar
• Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Man Care. 1998;4:345–355.
   PubMed Web of Science ®Google Scholar
• Palmer CS, Brunner E, Ruı́z-Flores LG, et al. A cost-effectiveness clinical decision analysis model for treatment of schizophrenia. Arch Med Res. 2002;33(6):572–580.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005;25(5):427–434.
   PubMed Web of Science ®Google Scholar
• De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics. 2005;23(1):35–47.
   PubMedGoogle Scholar
• Vera‐Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health. 2004;7(5):569–584.
   PubMed Web of Science ®Google Scholar
• van der Lee A, de Haan L, Beekman A. Schizophrenia in the Netherlands: continuity of Care with Better Quality of Care for Less Medical Costs. PloS One. 2016;11(6):e0157150–e0157150. . PubMed PMID: 27275609
   PubMed Web of Science ®Google Scholar
• Yung AR, Phillips LJ, Yuen HP, et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004 Apr 01;67(2):131–142. .
   PubMed Web of Science ®Google Scholar
• Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185(4):291–297.
   PubMed Web of Science ®Google Scholar
• Lee TY, Lee J, Kim M, et al. Can we predict psychosis outside the clinical high-risk state? A systematic review of non-psychotic risk syndromes for mental disorders. Schizophr Bull. 2018;44(2):276–285.
   PubMed Web of Science ®Google Scholar